drugset
drugset / Trial / NCT00003225

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

NCT00003225 ↗

Phase 1/2 Completed 23 enrolled Jonsson Comprehensive Cancer Center ALZA · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.

Timeline

Start
1997-07
Primary completion
2000-03
Completion
2001-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 250 mg/m2 Intravenous
Subject amifostine Unknown 740 mg/m2 Intravenous

Indications

colorectal cancer